Trastuzumab BS Specific Use Results Survey

Trastuzumab BS 60mg,150mg NK for intravenous infusion. Long-term specific use results survey targeting gastric cancer patients with confirmed HER2 overexpression. - /

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2071230094

Enrollment

150

Registered

2023-11-22

Start date

2018-11-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2 positive gastric cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HER2 positive gastric cancer

Exclusion criteria

Exclusion criteria: Not set: The following is set as a precaution when selecting patients.

Design outcomes

Primary

Measure	Time frame
Safety: Adverse events Efficacy: tumor reduction effect, best overall effect	—

Countries

Japan

Contacts

Public ContactTatsuo Haneji

NIPPON KAYAKU CO., LTD.

tatsuo.haneji@nipponkayaku.co.jp+81-8070218144

Outcome results